Renata Abrahão1,2, Raul C Ribeiro3, Bruno C Medeiros4, Ruth H Keogh5, Theresa H M Keegan2,6. 1. Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom. 2. Cancer Prevention Institute of California, Fremont, California. 3. Leukemia and Lymphoma Division, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee. 4. Division of Hematology, Stanford University School of Medicine, Stanford, California. 5. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom. 6. Division of Epidemiology, Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND: Findings from clinical trials and population-based studies have differed with regard to whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia (APL) has decreased in the era of all-trans retinoic acid and anthracycline-based chemotherapy. METHODS: Using data from the California Cancer Registry, the authors investigated 7-day and 30-day mortality and survival in 772 patients who were aged birth to 39 years when they were diagnosed with APL during 1988 to 2011. Logistic regression and Cox proportional models were used to examine the association of early death and survival, respectively, with sociodemographic and clinical factors. RESULTS: The overall 30-day mortality decreased significantly over time, from 26% (1988-1995) to 14% (2004-2011) (P =.004). On multivariable analysis, the odds of 30-day mortality were 3 times as high during 1988 through 1995 than 2004 through 2011 (P =.001). However, 7-day mortality did not improve over time (P =.229). When patients who died within 7 days of diagnosis were excluded, the 30-day mortality during 1996 to 2011 was 3% to 8%, which is similar to levels reported in clinical trials. Higher early death and lower survival were associated with a lack of health insurance (1996-2011) (early death odds ratio, 2.67; P =.031) and Hispanic race/ethnicity (early death odds ratio, 2.13; P =.014). Early death was not found to be associated with age, sex, socioeconomic status, or hospital type. Black patients also experienced worse survival. CONCLUSIONS: The findings of the current study revealed a decreased 30-day mortality during the all-trans retinoic acid era, but 7-day mortality remained high. Efforts to achieve equal outcomes in young patients with APL should focus on improving access to effective treatment, mainly among uninsured patients and those of Hispanic and black race/ethnicity.
BACKGROUND: Findings from clinical trials and population-based studies have differed with regard to whether mortality within 30 days of diagnosis (early death) of acute promyelocytic leukemia (APL) has decreased in the era of all-trans retinoic acid and anthracycline-based chemotherapy. METHODS: Using data from the California Cancer Registry, the authors investigated 7-day and 30-day mortality and survival in 772 patients who were aged birth to 39 years when they were diagnosed with APL during 1988 to 2011. Logistic regression and Cox proportional models were used to examine the association of early death and survival, respectively, with sociodemographic and clinical factors. RESULTS: The overall 30-day mortality decreased significantly over time, from 26% (1988-1995) to 14% (2004-2011) (P =.004). On multivariable analysis, the odds of 30-day mortality were 3 times as high during 1988 through 1995 than 2004 through 2011 (P =.001). However, 7-day mortality did not improve over time (P =.229). When patients who died within 7 days of diagnosis were excluded, the 30-day mortality during 1996 to 2011 was 3% to 8%, which is similar to levels reported in clinical trials. Higher early death and lower survival were associated with a lack of health insurance (1996-2011) (early death odds ratio, 2.67; P =.031) and Hispanic race/ethnicity (early death odds ratio, 2.13; P =.014). Early death was not found to be associated with age, sex, socioeconomic status, or hospital type. Black patients also experienced worse survival. CONCLUSIONS: The findings of the current study revealed a decreased 30-day mortality during the all-trans retinoic acid era, but 7-day mortality remained high. Efforts to achieve equal outcomes in young patients with APL should focus on improving access to effective treatment, mainly among uninsured patients and those of Hispanic and black race/ethnicity.
Keywords:
acute promyelocytic leukemia; adolescents; all-trans retinoic acid (ATRA); children; early death; health disparities; health insurance; survival; young adults
Authors: E Lengfelder; F Lo-Coco; L Ades; P Montesinos; D Grimwade; B Kishore; S M Ramadan; M Pagoni; M Breccia; A J G Huerta; A M Nloga; J D González-Sanmiguel; A Schmidt; J-F Lambert; S Lehmann; E Di Bona; B Cassinat; W-K Hofmann; D Görlich; M-C Sauerland; P Fenaux; M Sanz Journal: Leukemia Date: 2015-01-28 Impact factor: 11.528
Authors: S L Soignet; S R Frankel; D Douer; M S Tallman; H Kantarjian; E Calleja; R M Stone; M Kalaycio; D A Scheinberg; P Steinherz; E L Sievers; S Coutré; S Dahlberg; R Ellison; R P Warrell Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Eduardo M Rego; Haesook T Kim; Guillermo J Ruiz-Argüelles; Maria Soledad Undurraga; Maria del Rosario Uriarte; Rafael H Jacomo; Homero Gutiérrez-Aguirre; Raul A M Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Evandro M Fagundes; Maria de Lourdes Chauffaille; Carlos S Chiattone; Lem Martinez; Luis A Meillón; David Gómez-Almaguer; Hau C Kwaan; Javier Garcés-Eisele; Robert Gallagher; Charlotte M Niemeyer; Stanley L Schrier; Martin Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz Journal: Blood Date: 2013-01-14 Impact factor: 22.113
Authors: Jessica K Altman; Alfred Rademaker; Elizabeth Cull; Bing Bing Weitner; Yishai Ofran; Todd L Rosenblat; Augustin Haidau; Jae H Park; Sharona Lee Ram; James M Orsini; Sonia Sandhu; Rosalind Catchatourian; Steven M Trifilio; Nelly G Adel; Olga Frankfurt; Eytan M Stein; George Mallios; Tony Deblasio; Joseph G Jurcic; Stephen Nimer; Loann C Peterson; Hau C Kwaan; Jacob M Rowe; Dan Douer; Martin S Tallman Journal: Leuk Res Date: 2013-06-14 Impact factor: 3.156
Authors: Ayal A Aizer; Benjamin Falit; Mallika L Mendu; Ming-Hui Chen; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Neil E Martin; Quoc-Dien Trinh; Brian M Alexander; Paul L Nguyen Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Renata Abrahão; Daphne Y Lichtensztajn; Raul C Ribeiro; Neyssa M Marina; Ruth H Keogh; Rafael Marcos-Gragera; Sally L Glaser; Theresa H M Keegan Journal: Pediatr Blood Cancer Date: 2015-04-20 Impact factor: 3.838
Authors: Elysia M Alvarez; Marcio Malogolowkin; Jeffrey S Hoch; Qian Li; Ann Brunson; Brad H Pollock; Lori Muffly; Ted Wun; Theresa H M Keegan Journal: JCO Oncol Pract Date: 2020-06-11
Authors: S Lehmann; S Deneberg; P Antunovic; Å Rangert-Derolf; H Garelius; V Lazarevic; K Myhr-Eriksson; L Möllgård; B Uggla; A Wahlin; L Wennström; M Höglund; G Juliusson Journal: Leukemia Date: 2017-02-24 Impact factor: 11.528
Authors: Maya Schulpen; Bianca F Goemans; Gertjan J L Kaspers; Marc H G P Raaijmakers; C Michel Zwaan; Henrike E Karim-Kos Journal: Int J Cancer Date: 2021-12-16 Impact factor: 7.316
Authors: Renata Abrahão; Ruth H Keogh; Daphne Y Lichtensztajn; Rafael Marcos-Gragera; Bruno C Medeiros; Michel P Coleman; Raul C Ribeiro; Theresa H M Keegan Journal: Br J Haematol Date: 2016-02-05 Impact factor: 8.615
Authors: Neela L Penumarthy; Robert E Goldsby; Stephen C Shiboski; Rosanna Wustrack; Patricia Murphy; Lena E Winestone Journal: Cancer Med Date: 2019-12-15 Impact factor: 4.452